October 2021 Promotion of ketamine by Save Minds UK
Published 14 December 2021
© Crown copyright 2021
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/advertising-investigations-october-2021/october-2021-promotion-of-ketamine-by-save-minds-uk
MHRA received a complaint concerning advertising of the prescription-only medicine ketamine (including as a treatment for conditions outside the licensed indications) by Save Minds via their website homepage, social media and Google listings for the clinic. Regulation 284 of the Human Medicines Regulations 2012 prohibits advertisements to the public that are likely to lead to the use of a prescription-only medicine.
MHRA upheld the complaint. Save Minds UK confirmed that they would review their advertising to ensure that prescription-only medicines are not promoted to the public, in line with our guidance for treatment-service providers outlined in Appendix 6 of the MHRA Blue Guide.